Abbott Agrees to $385 Million Settlement Over Baby Formula Plant
Abbott Laboratories has agreed to a $385 million settlement linked to legal claims surrounding its Sturgis, Michigan, baby formula facility and the 2022 recall.
Abbott Laboratories has agreed to pay $385 million to settle legal claims connected to its Sturgis, Michigan, baby formula manufacturing facility, bringing a major chapter of the company's 2022 formula crisis closer to a conclusion.
The Sturgis plant, which was one of the largest baby formula manufacturing facilities in the United States, became the center of regulatory scrutiny in early 2022. The situation contributed to a nationwide shortage of infant formula and prompted a major recall of powdered formula products.
The settlement follows legal action involving the US Department of Justice, individual claimants and attorneys general from several states. Abbott has maintained that the agreement does not represent an admission of wrongdoing or liability.
What happened at Abbott's Sturgis facility?
Abbott's Sturgis facility in Michigan became the focus of a Food and Drug Administration investigation in early 2022. The company subsequently shut down the plant in February of that year.
The closure had significant consequences for the US infant formula market. Abbott was a major supplier, with products including Similac, one of the country's best-known infant formula brands.
When production stopped, the disruption came at a particularly difficult time. Supply chains were already under pressure following the COVID-19 pandemic, while consumer stockpiling and other distribution challenges had contributed to shortages.
The combination of reduced domestic production and existing supply problems created serious difficulties for parents and caregivers trying to find infant formula.
How did the 2022 formula shortage affect the US?
The Sturgis shutdown played a major role in an already challenging US baby formula supply situation.
As Abbott's facility remained closed, retailers across the country experienced shortages of powdered infant formula. Parents were left searching multiple stores for products, while some families struggled to find the specific formulas required by their babies.
The federal government took several steps to increase supplies.
The Biden administration eased certain import restrictions to allow more formula manufactured overseas to enter the US. The government also arranged air shipments of formula from Europe and used emergency measures designed to increase domestic production and distribution.
These actions were intended to stabilize the market while Abbott worked to restart operations at Sturgis.
Abbott's Sturgis plant eventually reopened
Abbott's Michigan facility was reopened in June 2022, several months after the shutdown.
The return of the plant was an important step in restoring domestic infant formula production. However, the broader supply disruption demonstrated how dependent the US market could be on a relatively small number of major manufacturers.
The episode also increased public attention on food safety procedures, regulatory oversight and the resilience of the infant formula supply chain.
Because infant formula is a critical food product for babies who depend on it for nutrition, disruptions can have consequences far beyond ordinary retail shortages.
What does the $385 million settlement cover?
The newly announced settlement involves legal claims related to the investigation and events surrounding Abbott's Sturgis facility.
According to the company, the agreement resolves litigation brought by certain relators as well as attorneys general representing multiple states.
Abbott has emphasized that the settlement does not include a finding of fault or liability.
That distinction is important. A settlement allows parties to resolve legal disputes without necessarily establishing that the company committed the alleged wrongdoing.
The financial agreement nevertheless represents a substantial resolution of claims associated with one of the most significant infant formula supply disruptions in recent US history.
Abbott disputes claims involving Cronobacter bacteria
The safety of infant formula was a central concern during the 2022 crisis, particularly because of scrutiny surrounding Cronobacter sakazakii, a bacterium that can cause serious illness in infants.
Abbott said on Monday that regulatory testing of unopened formula retrieved from homes involved in investigations connected to the 2022 recall produced negative results for Cronobacter sakazakii.
The company also stated that no unopened, distributed Abbott formula products have ever tested positive for the bacterium.
These statements form part of Abbott's position regarding the safety concerns that emerged during the investigation.
Cronobacter infections are uncommon but can be particularly dangerous for newborns and young infants. The potential severity of such infections makes contamination controls and testing especially important in infant formula manufacturing.
Justice Department investigation has ended
The legal and regulatory fallout from the Sturgis situation extended beyond the original plant closure.
A criminal investigation by the US Department of Justice was subsequently conducted. According to the information provided by Abbott, that investigation has since been closed.
The conclusion of the criminal investigation and the new civil settlement represent significant developments in the long-running controversy surrounding the facility.
However, the settlement does not erase the wider questions raised by the 2022 formula shortage about manufacturing capacity, food safety oversight and supply chain resilience.
Why the Abbott settlement matters
The $385 million agreement is significant not only because of its size, but also because of what the Sturgis shutdown revealed about the US infant formula market.
Infant formula is an essential product for millions of families. When a major manufacturing facility closes unexpectedly, the impact can spread quickly through retailers, hospitals and households.
The 2022 shortage also demonstrated the importance of having alternative sources of production. Government measures to increase imports and accelerate supplies from other countries highlighted the challenges involved in rapidly replacing lost domestic capacity.
For manufacturers, regulators and policymakers, the episode may serve as a reminder that food safety and supply security need to be considered together.
What happens next for Abbott?
The settlement allows Abbott to resolve a significant group of legal claims while continuing its operations in the infant nutrition market.
The company remains a major player in the US formula industry, and the Sturgis facility continues to be an important part of its manufacturing network.
For consumers, the focus is likely to remain on product safety, reliable availability and confidence in the companies responsible for producing infant nutrition products.
The 2022 crisis was a reminder that a problem at a single major facility can have nationwide consequences. The new settlement may close an important legal chapter, but the lessons from the shortage are likely to continue influencing discussions about the US baby formula supply chain.
Frequently Asked Questions
Why did Abbott close its Sturgis plant?
Abbott closed its Sturgis, Michigan, facility in February 2022 after the FDA began an investigation into conditions at the plant. The closure contributed significantly to the US infant formula shortage.
How much is Abbott paying in the settlement?
Abbott has agreed to a $385 million settlement resolving legal claims associated with the Sturgis facility and the events surrounding the 2022 formula crisis.
Was Abbott found liable?
Abbott has stated that the settlement contains no finding of fault or liability. A settlement itself does not necessarily mean that the company admitted wrongdoing.
What is Cronobacter sakazakii?
Cronobacter sakazakii is a bacterium that can cause serious infections, particularly in newborns and young infants. It became a major focus of concern during the 2022 infant formula investigation.
Is Abbott's Sturgis facility open?
The facility reopened in June 2022 after being closed for several months.
What caused the 2022 US baby formula shortage?
The shortage had several contributing factors, including the Abbott plant shutdown, existing supply chain pressures, pandemic-related disruptions and consumer stockpiling.
Source: The Independent on 14 September 2026, along with information attributed to Abbott Laboratories and the US regulatory and legal proceedings.
Disclaimer: This article is provided for general informational purposes only. It should not be considered legal, medical or financial advice. Details surrounding ongoing or recently resolved legal matters may change as additional information becomes available.